WESTON, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the commencement of a new human subject study for its inhalation therapy program targeting asthma and chronic obstructive pulmonary disease (COPD). This advancement builds on the promising results from a previous clinical study and reflects the company's commitment to improving the lives of individuals affected by these respiratory conditions.
"We are proud to continue advancing our asthma and COPD inhaled drug program, achieving key clinical development milestones on schedule,” said Xian-Ming Zeng, Ph.D., CEO of Transpire Bio. "These accomplishments mark an important step toward our vision of becoming a global leader in inhalation medicine.”
In addition to the asthma and COPD program, Transpire Bio is developing therapies for other diseases with significant unmet needs. These efforts leverage the company's proprietary drug delivery platforms and its robust manufacturing and research capabilities.
About Transpire Bio Inc.
Transpire Bio Inc. is a U.S.-based, clinical-stage biopharmaceutical company headquartered in Weston, Florida. The company specializes in inhaled drug delivery, aiming to enhance patient access to vital therapies and address serious medical conditions with limited treatment options. Transpire Bio's innovative technology portfolio includes dry powder inhalers, metered-dose inhalers, and soft-mist inhalers.
For more information, visit www.transpirebio.com.
Contacts
Corporate
Email: info@transpirebio.com
Phone: +1 954.908.2233
Investor Relations
Jeremy Feffer, Managing Director
LifeSci Advisors
Email: jfeffer@lifesciadvisors.com
